Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000–2013

BMC Cancer

Research Article

Tumas Beinortas¹  Rolandas Gerbutavičius²  Mindaugas Jurgutis³  Tadas Žvirblis⁴  Ilma Tavorienė⁴  Laimonas Griškevičius⁵ 

[1] Clinical Medical School, University of Oxford, Oxford, UK;Centre for Evidence-Based Medicine, Clinics of Internal, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, M. K. Ciurlionio str. 21, 03101, Vilnius, Lithuania;Clinics of Oncology and Hematology, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Eivenių g. 2, 50009, Kaunas, Lithuania;Department of Oncology Haematology, Klaipeda Seamen Hospital, Liepojos 45, 92288, Klaipeda, Lithuania;Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Santariskiu 2, 08661, Vilnius, Lithuania;Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Santariskiu 2, 08661, Vilnius, Lithuania;Clinics of Internal, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, M. K. Ciurlionio str. 21, 03101, Vilnius, Lithuania;

关键词: Chronic myeloid leukemia;    Tyrosine kinase inhibitors;    Survival;    Lithuania;    Drug penetrance;    Drug availability;    Europe;   

DOI  :  10.1186/s12885-016-2238-9

 received in 2015-11-16, accepted in 2016-03-01,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundCurrently available chronic myeloid leukaemia (CML) survival reports have originated from more affluent countries. Herein we report the entire country data on incidence and survival of CML, as well as penetrance of tyrosine kinase inhibitors (TKIs) in Lithuania.MethodsWe analyzed all patients (N = 601) from the national haematological disease monitoring system who were diagnosed with CML between 2000 and 2013. Crude (CR) and age-standardized (weighted) (ASW(R)) incidence and mortality rates, as well as 1-, 5-, and 10-year relative survival rates (RSR) were calculated. Information on TKI penetration is also reported.ResultsThroughout the entire 2000–2013 period the median age at diagnosis of CML patients was 62 years. The respective incidence and mortality CRs were 1.28 and 0.78, both characterized by decreasing trends over the observation period. A 5-year RSR increased from 0.33 [95 % CI, 0.27–0.40] in 2000–2004 to 0.55 [95 % CI, 0.47–0.63] in 2005–2009. However, the respective 5-year RSRs for patients aged 65–74 and ≥75 were only 0.33 [95 % CI, 0.24–0.42] and 0.18 [95 % CI 0.07–0.23] during the entire study period. TKI penetrance for CML patients grew from 1.5 % in 2000–2004 to 30.6 % in 2005–2009 and 69.1 % in 2010–2013. TKI penetrance was low in the older age groups (60 % for the 65–74 and 19 % for the ≥75 patient group, in 2010–2013).ConclusionRelative CML survival in Lithuania steadily improved and paralleled the increase in TKI treatment availability. Patients above 64 years rarely received TKIs and their relative survival remained low throughout the observation period. The latency of TKI availability may have influenced the survival trends.

【 授权许可】

CC BY   
© Beinortas et al. 2016